Previous close | 3.9500 |
Open | 3.8500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 165.00 |
Expiry date | 2025-01-17 |
Day's range | 3.8500 - 4.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively.
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...